A pregnant patient without HIV reports ongoing receptive vaginal sex with a partner of unknown HIV status and requests HIV pre-exposure prophylaxis (PrEP). She prefers an injectable option if it is effective and safe in pregnancy. Which statement best reflects current guidance and evidence for PrEP options in this setting? A. Only daily oral tenofovir disoproxil fumarate-emtricitabine is recommended for receptive vaginal sex during pregnancy; injectable options are not recommended B. Shared decision-making is endorsed, and long-acting cabotegravir and lenacapavir are effective for preventing HIV through vaginal exposure with no increase in adverse birth outcomes identified in trial participants who became pregnant C. On-demand dosing of tenofovir alafenamide-emtricitabine is preferred during pregnancy because it has the most efficacy data for vaginal exposure D. Injectable PrEP is contraindicated in pregnancy due to increased adverse birth outcomes Give your answer in the comments! 👇 #ClinicalChallenge #Obstetrics #MedEd